PTPRC and cancer: Out of 30 biopsies, cancer cell islets revealed CD45+ infiltration of 40% in 18 ‘inflamed’ samples, between 0–25% in 9 ‘immune-excluded’ samples, and 0–10% in 3 with ‘desert’ profiles (Figure S3a,b).